The pharmacodynamics, safety and pharmacokinetics of single doses of the motilin agonist, camicinal, in type 1 diabetes mellitus with slow gastric emptying
- 13 April 2016
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 173 (11), 1768-1777
- https://doi.org/10.1111/bph.13475
Abstract
Here we have investigated the pharmacokinetics, pharmacodynamics and safety of single doses of camicinal in type 1 diabetes mellitus (T1DM) patients with a history of slow gastric emptying with symptoms consistent with gastroparesis. In a randomized, double-blind, placebo-controlled, incomplete block, three-period, two-centre crossover study, patients received oral administration of placebo and two of the three possible doses of camicinal (25, 50 or 125 mg). Gastric emptying ((13) C-octanoic acid breath test), pharmacokinetics and safety were primary outcomes. Nine of the 10 patients enrolled completed the study. Gastric half-emptying time decreased by -95 min (95% CI: -156.8, -34.2) after a single dose of camicinal 125 mg compared with placebo (52 vs. 147 min, P < 0.05), representing a 65% improvement. A decrease of the gastric half-emptying time compared with placebo (approximately 39 min) was observed with camicinal 25 and 50 mg, representing a 27% reduction for both doses (not statistically significant). A positive exposure-response relationship was demonstrated across all doses. The effects of camicinal on gastric half-emptying time were not influenced by fasting glucose levels. Single doses up to 125 mg were well tolerated. Camicinal was well absorbed, exhibiting linear and approximately dose-proportional pharmacokinetic characteristics and a clear exposure-response relationship with gastric emptying. Camicinal significantly accelerated gastric emptying of solids in T1DM patients following administration of a single oral dose. Camicinal was well tolerated and exhibited similar pharmacokinetic characteristics in diabetic patients to those previously reported in healthy volunteers.This publication has 50 references indexed in Scilit:
- The relationship between gastric motility and nausea: Gastric prokinetic agents as treatmentsEuropean Journal of Pharmacology, 2013
- Gastrointestinal complications of diabetes mellitusWorld Journal of Diabetes, 2013
- Regional‐ and agonist‐dependent facilitation of human neurogastrointestinal functions by motilin receptor agonistsBritish Journal of Pharmacology, 2012
- Epidemiology, Mechanisms, and Management of Diabetic GastroparesisClinical Gastroenterology and Hepatology, 2011
- Efficacy of mitemcinal, a motilin agonist, on gastrointestinal symptoms in patients with symptoms suggesting diabetic gastropathy: a randomized, multi‐center, placebo‐controlled trialAlimentary Pharmacology & Therapeutics, 2007
- Stool Form Scale as a Useful Guide to Intestinal Transit TimeScandinavian Journal of Gastroenterology, 1997
- EM523L, a nonpeptide motilin agonist, stimulates gastric emptying and pancreatic polypeptide secretionPeptides, 1996
- Gastric emptying response to variable oral erythromycin dosing in diabetic gastroparesisDigestive Diseases and Sciences, 1995
- Improvement of Gastric Emptying in Diabetic Gastroparesis by ErythromycinThe New England Journal of Medicine, 1990
- Complete identification of endocrine cells in the gastrointestinal tract using semithin-thin sections to identify motilin cells in human and animal intestine.Gut, 1975